Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
Nusse RoelandDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000861 · edgar.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000861 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,973 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
HIGGINS JOHN LDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000860 · edgar.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000860 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
HOLBROOK KAREN ADirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000859 · edgar.xml · derivative · entry 2 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:17 UTC |
HOLBROOK KAREN ADirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000859 · edgar.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC |
STEER RANDOLPH CDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000857 · edgar.xml · derivative · entry 2 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC |
STEER RANDOLPH CDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000857 · edgar.xml · nonDerivative · entry 1 STEER RANDOLPH C · CIK 0001198762 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,973 Read SEC document |
| October 19, 2016 Filed Oct 31, 2016 21:10 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $104.71 | $10,471.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,215 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 20:40 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $108.91 | $10,891.00 |
DisclosureSEC source: 0000914190-16-000839 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 21:27 UTC |
Gould Kevin SSVP Clinical Controls
|
SaleCommon Stock | 524 | $110.50 | $57,903.57 |
DisclosureSEC source: 0000914190-16-000832 · edgar.xml · nonDerivative · entry 1 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.4934 to $110.5402 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 833 shares of restricted stock units that vest on 7/9/17 and 834 shares of restricted stock units that vest on 7/9/18. Read SEC document |
| September 08, 2016 Filed Sep 12, 2016 21:27 UTC |
HIGGINS JOHN LDirector
|
SaleCommon Stock | 1,700 | $109.83 | $186,715.93 |
DisclosureSEC source: 0000914190-16-000831 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,359 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.35 to $110.2867 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,613 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 14 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,613 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 2,613 | $107.15 | $279,986.61 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 5 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.38 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 2,613 | $65.47 | $171,073.11 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 4 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,467 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 15 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,467 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,387 | $0.00 Strike: $65.47 | $0.00 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · derivative · entry 13 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613 Underlying: Common Stock · 2,387 shares Expires 2018-10-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
SaleCommon Stock | 3,854 | $107.18 | $413,052.45 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 3 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.46 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 1,467 | $66.59 | $97,687.53 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 20:36 UTC |
BAUMGARTNER ROBERT VDirector
|
Exercise / conversionCommon Stock | 2,387 | $65.47 | $156,276.89 |
DisclosureSEC source: 0000914190-16-000813 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
GrantRestricted Stock Units · Derivative | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 11 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,111 Underlying: Common Stock · 2,111 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
GrantStock Option (Right to Buy) · Derivative | 13,028 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 10 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,028 Underlying: Common Stock · 13,028 shares Expires 2023-08-18 F9 · derivative.exercise_date: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 18, 2016 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
GrantStock Option (Right to Buy) · Derivative | 17,371 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 9 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,371 Underlying: Common Stock · 17,371 shares Expires 2023-08-18 F8 · derivative.exercise_date: Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.